Researchers based at Northwestern University Feinberg School of Medicine have discovered that a lack of contact between mitochondria and lysosomes in the cells of patients with a genetic form of Parkinson’s disease likely contributed to their symptoms. Read More
Researchers from the Chinese University of Hong Kong have identified the Carnobacterium maltaromaticum bacterium as a potential oral probiotic prophylactic to increase vitamin D production and reinvigorate gut microbiota to prevent colorectal cancer (CRC) in women. Read More
There is a strong link between the loss of TAR DNA-binding protein 43 (TDP-43) function and the development of frontotemporal dementia (FTD)... Read More
Researchers from Wuhan Institute of Biological Products Co. Ltd. and affiliated organizations presented preclinical data for the novel Madin... Read More
Since both amyloid-β (Aβ) and tau are involved in the progression of Alzheimer’s disease (AD), it is believed that simultaneous disruption of these... Read More
Newly formed Mage Biologics Inc. is set to receive investment of $28 million from TVM Capital Life Science and Tillotts Pharma AG. Mage plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (MAb) for an initial indication of ulcerative colitis. Read More
Plasmalogens are a type of phospholipid that play significant roles in membrane fluidity and cellular processes such as vesicular fusion and signal transduction. Previous studies with natural plasmalogens have shown their role in neuroinflammation and memory function improvement. Read More
Jeil Pharmaceutical Co. Ltd. has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, ulcerative colitis, rheumatoid arthritis, autoimmune disease, cardiovascular disorders and dermatological and inflammatory disorders and neurological disorders, among others. Read More
A Chiesi Farmaceutici SpA patent details cyclohexane acid derivatives acting as lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists and thus reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases. Read More
Sangamo Therapeutics Inc. and Chroma Medicine Inc. have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Read More
Galectin-3 (LGALS3) and/or galectin-9 (LGALS9) inhibitors are reported in a Galecto Biotech AB patent as potentially useful for the treatment of cancer, autoimmune disease, fibrosis, cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among others. Read More
Riparian Pharmaceuticals Inc., a Viva Biotech Holdings Group portfolio company, has entered into an exclusive license agreement and research agreement with Pfizer Inc. in cardiovascular disease. Read More
Research at Insilico Medicine Inc. has led to the development of CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disorders and inflammation. Read More
